On Mar, 30 2026, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced its continuous risk assessment report for Tianjin Pharmaceutical Group Finance Co., Ltd. (TPGF) covering the six-month period ended Dec, 31 2025.

The report states that TPGF – a related finance company providing deposit, settlement and credit services to the group under a three-year agreement effective Jul, 1 2023 – operated in full compliance with Chinese regulatory requirements and recorded no major operational risks or non-performing assets during the review period. All key prudential indicators exceeded the National Financial Regulatory Administration’s thresholds, including a capital adequacy ratio of 27.48% (minimum: 10.5%) and a liquidity ratio of 63.62% (minimum: 25%).

As at Dec, 31 2025, TPGF’s total assets stood at RMB4.62 billion, total liabilities at RMB3.47 billion and net assets at RMB1.14 billion, translating to an asset-liability ratio of 75.22%. For full-year 2025, the finance company generated revenue of RMB65.75 million and net profit of RMB24.19 million; in the first two months of 2026, revenue was RMB8.48 million with net profit of RMB28.13 million.

Tianjin Pharmaceutical Da Ren Tang’s deposits with TPGF amounted to roughly RMB1.40 billion at year-end 2025, while it had no outstanding loans from the finance company. The board said these deposits remained safe and liquid, with associated risks considered controllable.

The company will continue to prepare and disclose risk assessment reports on TPGF every six months and will activate contingency plans if any abnormalities arise.